NCT04469582|UnknownDMC
Loading search results
Sponsor study identifier
observational
113
1 country
1
Study Start
April 1, 2009
Actual (reported)Primary Completion
September 9, 2020
Actual (reported)Study Completion
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The investigators conducted a prospective study which included all patients diagnosed with biopsy-proven BP in the Dermatology Department of Attikon hospital between April 1, 2009 and December 31, 2019. 113 consecutive patients with BP were identified. The investigators included the patients with type 2 diabetes and investigated the percentage of patients who were under treatment with DPP4-is. The specific DPP4-i prescribed was also documented.Medical information including patients' age, sex, other comorbidities and concomitant medications were also recorded. Furthermore, the investigators evaluated the effect of different types of treatment (topical steroids, systemic corticosteroids, immunosuppressive agents) on bullous pemphigoid.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 1, 2009
Actual (reported)July 9, 2020
Actual (reported)July 14, 2020
Actual (reported)September 9, 2020
Actual (reported)December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Τhe correlation between the use of DPP-4is and the development of Bullous pemphigoid
The investigators assessed the percentage of patients who were under treatment with DPP4-is among patients with bullous pemphigoid
baseline
In the study included all patients diagnosed with biopsy-proven BP in the Dermatology Department of Attikon hospital between April 1, 2009 and December 31, 2019.
"Attikon" University General Hospital
Athens, Attica, 12462, Greece
Vaia Lambadiari, MD,PhD
2nd department of internal medicine,University of Athens,Greece
Evangelia Papadavid, MD,PhD
2nd department of dermatology and venereology,University of Athens, Greece
Aikaterini Kountouri, MD
2nd department of internal medicine,University of Athens,Greece
Emmanouil Korakas, MD
2nd department of internal medicine,University of Athens,Greece
First Submitted
July 9, 2020
First Posted
July 14, 2020
Study Start
April 1, 2009
Actual (reported)Primary Completion
September 9, 2020
Actual (reported)Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
Contact the study team to confirm eligibility.
Sofia Theotokoglou
2nd department of dermatology and venereology,University of Athens, Greece
Konstantinos Theodoropoulos
2nd department of dermatology and venereology,University of Athens, Greece
Ignatios Ikonomidis, MD,PhD
2nd department of cardiology,University of Athens,Greece
Study Completion
December 31, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
September 23, 2020
Record last verified: 2020-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: